Efficacy of eribulin monotherapy for bone marrow carcinomatosis of breast cancer in a patient with Werner syndrome

Akihito Fujimi; Yasuhiro Nagamachi; Naofumi Yamauchi; Riku Hasebe; Naoki Onoyama; Naotaka Hayasaka; Teppei Matsuno; Kazuhiko Koike; Yoshiro Gotoh; Kohji Ihara; Junji Kato; Takuji Nishisato; Kazuyuki Murase; Goro Kutomi; Tokimasa Hida; Hisashi Uhara; Kohichi Takada

doi:10.1111/ggi.15070

Efficacy of eribulin monotherapy for bone marrow carcinomatosis of breast cancer in a patient with Werner syndrome

Geriatr Gerontol Int. 2025 Jan 6. doi: 10.1111/ggi.15070. Online ahead of print.

Authors

Akihito Fujimi¹, Yasuhiro Nagamachi¹, Naofumi Yamauchi¹, Riku Hasebe¹, Naoki Onoyama², Naotaka Hayasaka², Teppei Matsuno², Kazuhiko Koike², Yoshiro Gotoh², Kohji Ihara², Junji Kato², Takuji Nishisato², Kazuyuki Murase³, Goro Kutomi⁴, Tokimasa Hida⁵, Hisashi Uhara⁵, Kohichi Takada³

Affiliations

¹ Department of Hematology, Sapporo Kiyota Hospital, Sapporo, Japan.
² Department of Internal Medicine, Sapporo Kiyota Hospital, Sapporo, Japan.
³ Department of Medical Oncology, Sapporo Medical University, Sapporo, Japan.
⁴ Department of Surgery, Sapporo Medical University, Sapporo, Japan.
⁵ Department of Dermatology, Sapporo Medical University, Sapporo, Japan.

PMID: 39761950
DOI: 10.1111/ggi.15070

Abstract

Various complications and potential risks of serious adverse events lessens the intensity of chemotherapy in patients with Werner syndrome. Bone marrow carcinomatosis of breast cancer was developed in a patient with Werner syndrome. Eribulin proved well tolerated and effective in improving severe thrombocytopenia, leading to platelet transfusion-free status.

Publication types

Letter